Inhaler
Chiesi unveils 430M investment to revitalize Italian production site for inhaler, biologics manufacturing
Investments, Inhaler, Biological Factors, production
US FTC Intensifies Patent Crusade with Investigation into Teva’s Inhaler IP
US Federal Trade Commission, Teva Pharmaceuticals, Patent Investigation, Inhaler IP, Anticompetitive Practices, Generic Competition
AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation
Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices
Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.
Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction